MARY CROW

Summary

Affiliation: Hospital for Special Surgery
Country: USA

Publications

  1. ncbi request reprint Interferon-alpha in systemic lupus erythematosus
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Curr Opin Rheumatol 16:541-7. 2004
  2. ncbi request reprint Type I interferon in the pathogenesis of lupus
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY 10021 and Rheumatology Division, Department of Medicine, NewYork Presbyterian Weill Cornell Medical Center, New York, NY 10065
    J Immunol 192:5459-68. 2014
  3. pmc Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus
    Silvia N Kariuki
    University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Arthritis Res Ther 12:R151. 2010
  4. ncbi request reprint Academic rheumatology: not just a man's world
    Mary K Crow
    Mary Kirkland Center for Lupus Research, and Hospital for Special Surgery and Weill Medical College of Cornell University, New York, New York 10021, USA
    Arthritis Rheum 52:694-6. 2005
  5. ncbi request reprint Type I interferon in systemic lupus erythematosus
    M K Crow
    Autoimmunity and Inflammation Program, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Curr Top Microbiol Immunol 316:359-86. 2007
  6. ncbi request reprint Interferon pathway activation in systemic lupus erythematosus
    Mary K Crow
    Hospital for Special Surgery, New York, NY 10021, USA
    Curr Rheumatol Rep 7:463-8. 2005
  7. pmc Interferon-alpha: a therapeutic target in systemic lupus erythematosus
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Rheumatology Division, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Rheum Dis Clin North Am 36:173-86, x. 2010
  8. ncbi request reprint Long interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune disease
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York 10021, USA
    Autoimmunity 43:7-16. 2010
  9. ncbi request reprint Mentors and heroes: the foundation and future of rheumatology
    Mary K Crow
    Hospital for Special Surgery, New York, New York 10021, USA
    Arthritis Rheum 56:1037-43. 2007
  10. ncbi request reprint Modification of accessory molecule signaling
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Department of Medicine, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Springer Semin Immunopathol 27:409-24. 2006

Research Grants

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Interferon-alpha in systemic lupus erythematosus
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Curr Opin Rheumatol 16:541-7. 2004
    ....
  2. ncbi request reprint Type I interferon in the pathogenesis of lupus
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY 10021 and Rheumatology Division, Department of Medicine, NewYork Presbyterian Weill Cornell Medical Center, New York, NY 10065
    J Immunol 192:5459-68. 2014
    ..This expanding knowledge of the role of IFN-I and the innate immune response suggests candidate therapeutic targets that are being tested in lupus patients. ..
  3. pmc Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus
    Silvia N Kariuki
    University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Arthritis Res Ther 12:R151. 2010
    ..These two heritable risk factors are shared between ancestral backgrounds. The aim of the study was to detect genetic factors associated with autoantibody profiles and serum IFN-α in SLE...
  4. ncbi request reprint Academic rheumatology: not just a man's world
    Mary K Crow
    Mary Kirkland Center for Lupus Research, and Hospital for Special Surgery and Weill Medical College of Cornell University, New York, New York 10021, USA
    Arthritis Rheum 52:694-6. 2005
  5. ncbi request reprint Type I interferon in systemic lupus erythematosus
    M K Crow
    Autoimmunity and Inflammation Program, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Curr Top Microbiol Immunol 316:359-86. 2007
    ....
  6. ncbi request reprint Interferon pathway activation in systemic lupus erythematosus
    Mary K Crow
    Hospital for Special Surgery, New York, NY 10021, USA
    Curr Rheumatol Rep 7:463-8. 2005
    ..In addition, investigations of the mechanisms of induction of IFN pathway activation are suggesting clues to the triggers of autoimmunity in SLE...
  7. pmc Interferon-alpha: a therapeutic target in systemic lupus erythematosus
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Rheumatology Division, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Rheum Dis Clin North Am 36:173-86, x. 2010
    ..Meanwhile, promising clinical trials are moving forward to test the safety and efficacy of monoclonal antibody inhibitors of IFN-alpha. Other therapeutic approaches to target the IFN pathway may follow close behind...
  8. ncbi request reprint Long interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune disease
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York 10021, USA
    Autoimmunity 43:7-16. 2010
    ..Induction of type I IFN by L1-enriched nucleic acids through TLR-independent pathways could represent a first step in the complex series of events leading to systemic autoimmune disease...
  9. ncbi request reprint Mentors and heroes: the foundation and future of rheumatology
    Mary K Crow
    Hospital for Special Surgery, New York, New York 10021, USA
    Arthritis Rheum 56:1037-43. 2007
  10. ncbi request reprint Modification of accessory molecule signaling
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Department of Medicine, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Springer Semin Immunopathol 27:409-24. 2006
    ..Further elucidation of the complexities of members of the accessory molecule families and their functions should lead to an ever greater capacity for therapeutic modulation of the immune response in autoimmune and inflammatory diseases...
  11. pmc Developments in the clinical understanding of lupus
    Mary K Crow
    Autoimmunity and Inflammation Program, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Arthritis Res Ther 11:245. 2009
    ..Nonetheless, progress in understanding the underlying immunopathogenesis of lupus and its impact on clinical disease has accelerated the pace of clinical research to improve the outcomes of patients with systemic lupus erythematosus...
  12. ncbi request reprint Anticyclic citrullinated peptide antibody-negative rheumatoid arthritis: clues to disease pathogenesis
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Curr Rheumatol Rep 10:165-7. 2008
  13. ncbi request reprint Regulation of CD40 ligand expression in systemic lupus erythematosus
    M K Crow
    Department of Medicine, Hospital for Special Surgery and Weill Medical College of Cornell University, New York City, New York, USA
    Curr Opin Rheumatol 13:361-9. 2001
    ..More complete characterization of the mechanisms that regulate the magnitude and duration of CD40L expression should suggest new approaches to modulate this promising therapeutic target...
  14. ncbi request reprint Studies of autologous T cell activation in the Kunkel laboratory
    M K Crow
    The Mary Kirkland Center for Lupus Research, Rheumatology Research Program, Hospital for Special Surgery, New York, NY 10021, USA
    Lupus 12:163-9. 2003
    ....
  15. pmc Type I interferon in organ-targeted autoimmune and inflammatory diseases
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Weill Cornell Medical College, 535 East 70th Street, New York, NY 10021, USA
    Arthritis Res Ther 12:S5. 2010
    ....
  16. pmc Microarray analysis of gene expression in lupus
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, USA
    Arthritis Res Ther 5:279-87. 2003
    ....
  17. ncbi request reprint Type I interferon and autoimmune disease
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, USA
    Autoimmunity 36:445-6. 2003
  18. ncbi request reprint Microarray analysis of interferon-regulated genes in SLE
    Mary K Crow
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY, USA
    Autoimmunity 36:481-90. 2003
    ..Definition of the nature of the major IFNs, or other factors, that drive the IFN-regulated gene expression signature noted in SLE is an important area for investigation that may lead to new approaches to targeted therapy of SLE...
  19. ncbi request reprint Costimulatory molecules and T-cell-B-cell interactions
    Mary K Crow
    Mary Kirkland Center, for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Rheum Dis Clin North Am 30:175-91, vii-viii. 2004
    ..Knowledge of the structure and function of these costimulatory molecules can be used to manipulate immune function and inhibit autoimmunity and inflammation in the setting of disease...
  20. ncbi request reprint Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies
    Jing Hua
    Mary Kirkland Center for Lupus Research and Department of Medicine, Hospital for Special Surgery, and Weill Medical College of Cornell University, New York, New York 10021, USA
    Arthritis Rheum 54:1906-16. 2006
    ..To characterize these mediators, we developed an assay that measures the functional effects of plasma or serum components on the gene expression of cultured target cells...
  21. ncbi request reprint Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease
    Kyriakos A Kirou
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery and Weill Medical College of Cornell University, New York, New York, USA
    Arthritis Rheum 52:1491-503. 2005
    ..This study examined the hypothesis that increased disease severity and activity, as well as distinct autoantibody specificities, characterize SLE patients with activation of the type I IFN pathway...
  22. ncbi request reprint Distinct inflammatory gene pathways induced by particles
    Andrew D Pearle
    Shoulder and Sports Medicine Service, Hospital for Special Surgery, New York, NY 10021, USA
    Clin Orthop Relat Res 458:194-201. 2007
    ..The induction of T cell activation by titanium particles suggests lymphocytes may contribute to the inflammation that mediates osteolysis in patients with metallic particulate debris after total joint replacement...
  23. pmc Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
    Robert F Spiera
    Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Ann Rheum Dis 70:1003-9. 2011
    ..To assess the safety and effectiveness of imatinib mesylate in the treatment of diffuse cutaneous systemic sclerosis (dcSSc)...
  24. pmc Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort
    Clio P Mavragani
    Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA
    Arthritis Rheum 62:392-401. 2010
    ..Since an interferon (IFN) signature is variably expressed among RA patients, we investigated whether plasma type I IFN activity might predict the response to TNF antagonist therapy...
  25. ncbi request reprint Measurement of cytokines in autoimmune disease
    Kyriakos A Kirou
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, USA
    Methods Mol Med 102:129-54. 2004
    ..Detailed methods are provided for these assays...
  26. ncbi request reprint Activation of type I interferon in systemic lupus erythematosus
    Kyriakos A Kirou
    Assistant Professor of Clinical Medicine and Assistant Scientist, Mary Kirkland Center for Lupus Research, Department of Medicine, Hospital for Special Surgery and Weill Medical College of Cornell University, 535 East 70th Street, New York, NY 10021, USA
    Expert Rev Clin Immunol 3:579-88. 2007
    ..First, IFN may be a useful biomarker of disease subtype and activity and, second, IFN is a rational target for therapeutic intervention. Cautious blockade of this pathway might eliminate an important contributor to autoimmunity...
  27. pmc Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept
    Clio P Mavragani
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Arthritis Rheum 56:3995-4004. 2007
    ..To address the hypothesis that tumor necrosis factor blockade can result in increased levels of interferon-alpha (IFNalpha) and BAFF, we quantified those mediators in plasma from etanercept- and placebo-treated SS patients...
  28. ncbi request reprint Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus
    Mary J Roman
    Division of Cardiology, Weill Medical College of Cornell University, The Hospital for Special Surgery, New York, NY 10021, USA
    N Engl J Med 349:2399-406. 2003
    ....
  29. ncbi request reprint Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus
    Kyriakos A Kirou
    Hospital for Special Surgery, and Weill Medical College of Cornell University, New York, New York 10021, USA
    Arthritis Rheum 50:3958-67. 2004
    ....
  30. pmc Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation
    David R Fernandez
    Division of Rheumatology, Department of Medicine, State University of New York, Syracuse, NY 13210, USA
    J Immunol 182:2063-73. 2009
    ..The results suggest that activation of mTOR causes the loss of TCRzeta in lupus T cells through HRES-1/Rab4-dependent lysosomal degradation...
  31. ncbi request reprint Arterial stiffness in chronic inflammatory diseases
    Mary J Roman
    Division of Cardiology, Weill Medical College, Cornell University, 525 East 68th St, New York, NY 10021, USA
    Hypertension 46:194-9. 2005
    ....
  32. ncbi request reprint Preclinical carotid atherosclerosis in patients with rheumatoid arthritis
    Mary J Roman
    Division of Cardiology, Weill Medical College of Cornell University, Hospital for Special Surgery, and The Rogosin Institute, New York, New York 10021, USA
    Ann Intern Med 144:249-56. 2006
    ..Rheumatoid arthritis is associated with increased morbidity and mortality because of cardiovascular disease, independent of traditional risk factors...
  33. ncbi request reprint Relationship of asymmetric dimethylarginine and homocysteine to vascular aging in systemic lupus erythematosus patients
    Michelle Perna
    Weill Cornell Medical College and Hospital for Special Surgery, New York, New York 10021, USA
    Arthritis Rheum 62:1718-22. 2010
    ..The aim of this study was to assess the relationship of ADMA and homocysteine to subclinical vascular disease in patients with SLE...
  34. ncbi request reprint Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus
    Mary J Roman
    Weill Medical College of Cornell University, and the Hospital for Special Surgery, New York, New York 10021, USA
    Arthritis Rheum 56:3412-9. 2007
    ..To determine the rate of atherosclerosis progression as well as the relationship of traditional risk factors, systemic lupus erythematosus (SLE)-related factors, and treatment to atherosis progression in SLE patients...
  35. ncbi request reprint T cell proliferation induced by autologous non-T cells is a response to apoptotic cells processed by dendritic cells
    Anna D Chernysheva
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Weill Medical College and Graduate School of Medical Sciences of Cornell University, New York, NY 10021, USA
    J Immunol 169:1241-50. 2002
    ..Induction of an in vivo autologous mixed lymphocyte reaction by caspase-modified self-Ags present in apoptotic cells may represent a mechanism to maintain peripheral immune tolerance...
  36. ncbi request reprint Ongoing immunoglobulin class switch DNA recombination in lupus B cells: analysis of switch regulatory regions
    Shiquan Liu
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY 10021, USA
    Autoimmunity 37:431-43. 2004
    ..These results support a role for exogenous signals, such as through CD40 ligation, rather than altered genomic sequence, in the increased production of class switched autoantibodies in SLE...
  37. ncbi request reprint Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system
    Kyriakos A Kirou
    Weill Medical College of Cornell University, New York, NY, USA
    Rheum Dis Clin North Am 32:103-19, ix. 2006
    ....
  38. ncbi request reprint Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus
    Afshin Farzaneh-Far
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York 10021, USA
    Arthritis Rheum 54:3918-25. 2006
    ..We undertook this study to examine the relationships of aPL with valvular, myocardial, and arterial disease in SLE...
  39. pmc Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction
    Rebecca L Rudominer
    Weill Cornell Medical College, New York, New York 10021, USA
    Arthritis Rheum 60:22-9. 2009
    ..This study was undertaken to investigate whether RA is associated with underlying structural and functional abnormalities of the left ventricle (LV)...
  40. ncbi request reprint Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound?
    Carla R Scanzello
    Hospital for Special Surgery, Division of Rheumatology, New York, New York, USA
    Curr Opin Rheumatol 20:565-72. 2008
    ..In this report, we review evidence that certain extracellular matrix components of joint tissues (hyaluronan and fibronectin) may act as TLR stimuli, and summarize recent literature implicating TLR activation in osteoarthritis...
  41. ncbi request reprint Systemic lupus erythematosus predicts increased left ventricular mass
    Janice Pieretti
    Division of Cardiology, Weill Medical College of Cornell University and the Hospital for Special Surgery, New York, NY 10021, USA
    Circulation 116:419-26. 2007
    ..Whether SLE alters left ventricular (LV) structure and function in the absence of valvular and clinical coronary artery disease is unknown...
  42. ncbi request reprint Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases
    Andreas Goules
    Department of Pathophysiology, School of Medicine, National University of Athens, 75 M Asias Street, 11527 Athens, Greece
    J Autoimmun 26:165-71. 2006
    ..Soluble CD40L is elevated in sera of SS and SLE patients but further investigation is needed to determine its possible role in SLE nephritis and Sjögren's syndrome...
  43. ncbi request reprint Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus
    Rengasamy Asokan
    Department of Medicine and Department of Immunology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA
    J Immunol 177:383-94. 2006
    ....
  44. pmc Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients
    Timothy B Niewold
    University of Chicago, Section of Rheumatology, Chicago, IL 60637, USA
    Arthritis Rheum 58:2481-7. 2008
    ..The aim of this study was to determine whether the IRF5 SLE risk haplotype mediates the risk of SLE by predisposing patients to the development of high levels of serum IFNalpha activity...
  45. ncbi request reprint Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE
    Jane Tian
    Inflammation and Autoimmune Group, Research Department, MedImmune, Gaithersburg, Maryland 20878, USA
    Nat Immunol 8:487-96. 2007
    ..Our data demonstrate a mechanism by which HMGB1 and RAGE activate plasmacytoid dendritic cells and B cells in response to DNA and contribute to autoimmune pathogenesis...
  46. doi request reprint Fast forward for systemic lupus erythematosus clinical trials
    Mary K Crow
    Nat Clin Pract Rheumatol 4:387. 2008
  47. pmc Early growth response-1 is required for CD154 transcription
    Randy Q Cron
    Division of Rheumatology, Children s Hospital of Philadelphia, PA 19104, USA
    J Immunol 176:811-8. 2006
    ..This has implications for selective targeting of Egr family members to control abnormal expression of CD154 in autoimmune diseases such as systemic lupus erythematosus...
  48. pmc Age- and sex-related patterns of serum interferon-alpha activity in lupus families
    Timothy B Niewold
    Section of Rheumatology, University of Chicago, Chicago, Illinois 60637, USA
    Arthritis Rheum 58:2113-9. 2008
    ..The purpose of this study was to determine whether serum IFNalpha activity in SLE patients and their healthy first-degree relatives is highest in early adulthood, when the incidence of SLE is greatest...
  49. pmc Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus
    Timothy B Niewold
    University of Chicago, Section of Rheumatology, Chicago, Illinois 60637, USA
    Arthritis Rheum 58:541-6. 2008
    ....
  50. ncbi request reprint Interferon-alpha: a new target for therapy in systemic lupus erythematosus?
    Mary K Crow
    Arthritis Rheum 48:2396-401. 2003
  51. doi request reprint Collaboration, genetic associations, and lupus erythematosus
    Mary K Crow
    N Engl J Med 358:956-61. 2008

Research Grants19

  1. Interferon in Systemic Lupus Erythematosus
    Mary K Crow; Fiscal Year: 2010
    ..Elucidation of this important pathway should lead to more targeted modulation of disease mediators in systemic autoimmune diseases. ..
  2. Interferon in Systemic Lupus Erythematosus
    MARY CROW; Fiscal Year: 2009
    ..Elucidation of this important pathway should lead to more targeted modulation of disease mediators in systemic autoimmune diseases. ..
  3. RHEUMATOLOGY RESEARCH TRAINING PROGRAM
    MARY CROW; Fiscal Year: 2007
    ..Support is requested for 3 MD, MD-PhD, or PhD trainees who will gain the skills required to make important advances in the health of patients with rheumatic disease. ..
  4. Interferon in Systemic Lupus Erythematosus
    MARY CROW; Fiscal Year: 2007
    ..Elucidation of this important pathway should lead to more targeted modulation of disease mediators in systemic autoimmune diseases. ..
  5. Premature Atherosclerosis in Rheumatic Diseases
    MARY CROW; Fiscal Year: 2006
    ..abstract_text> ..
  6. Interferon in Systemic Lupus Erythematosus
    MARY CROW; Fiscal Year: 2006
    ..Elucidation of this important pathway should lead to more targeted modulation of disease mediators in systemic autoimmune diseases. ..
  7. Premature Atherosclerosis in Rheumatic Diseases
    MARY CROW; Fiscal Year: 2005
    ..abstract_text> ..
  8. Premature Atherosclerosis in Rheumatic Diseases
    MARY CROW; Fiscal Year: 2004
    ..abstract_text> ..
  9. Identification of Rheumatic Disease Genes
    MARY CROW; Fiscal Year: 2004
    ..abstract_text> ..
  10. Premature Atherosclerosis in Rheumatic Diseases
    MARY CROW; Fiscal Year: 2003
    ..abstract_text> ..
  11. Fourth Biennial Arthritis Research Conference
    MARY CROW; Fiscal Year: 2003
    ..abstract_text> ..
  12. CD40 LIGAND IN SYSTEMIC LUPUS ERYTHEMATOSUS
    MARY CROW; Fiscal Year: 2002
    ..These studies should elucidate disease pathogenesis and identify new targets for therapy in SLE. ..
  13. CD40 LIGAND IN SYSTEMIC LUPUS ERYTHEMATOSUS
    MARY CROW; Fiscal Year: 2001
    ..These studies should elucidate disease pathogenesis and identify new targets for therapy in SLE. ..
  14. CD40 LIGAND IN SYSTEMIC LUPUS ERYTHEMATOSUS
    MARY CROW; Fiscal Year: 2000
    ..These studies should elucidate disease pathogenesis and identify new targets for therapy in SLE. ..
  15. CD40 LIGAND IN SYSTEMIC LUPUS ERYTHEMATOSUS
    MARY CROW; Fiscal Year: 1999
    ..These studies should elucidate disease pathogenesis and identify new targets for therapy in SLE. ..